Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
Ointment 20mg/g (2%)
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Eucrisa, or Crisaborole, is a topical prescription medication primarily used to treat mild to moderate atopic dermatitis, commonly known as eczema, in pediatric and adult patients.
It belongs to the class of non-steroidal phosphodiesterase 4 (PDE-4) inhibitors. The active ingredient works by increasing cyclic adenosine monophosphate (cAMP) levels and reducing inflammation involved in the immune response, relieving symptoms associated with eczema.
Fact Table | |
---|---|
Formula | C14H10BNO3 |
License | FDA approved |
Bioavailability | Low systemic absorption when used topically |
Legal status | Prescription only |
Chemical Name | 5-(4-Cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborole |
Elimination half-life | Approximately 3 hours (systemic absorption is low) |
Dosage (Strength) | 2% ointment |
Pregnancy | Consult a healthcare provider; limited data available |
Brands | Eucrisa |
Protein binding | Not specifically determined for topical use |
PubChem CID | 53386093 |
MedlinePlus | a617033 |
ChEBI | 132800 |
ATC code | D11AH05 |
DrugBank | DB11800 |
KEGG | D10319 |
Routes of administration | Topical |
Apply a thin layer to the affected area(s) twice daily.
Eucrisa is for external use only. Do not use in the eyes, ears, nose, vagina, or other mucus membranes.
The hands should be washed thoroughly after each application, and contact with the eyes, mouth, and other mucous membranes should be avoided.
Do not apply Eucrisa to open wounds or sores.
The active ingredient in Eucrisa is crisaborole.
Inactive ingredients include the following:
There are no significant drug-drug interactions between Eucrisa and other medications. However, tell your doctor and pharmacist about all other drugs you are taking before starting Eucrisa.
Patients using Eucrisa should exercise caution and inform their healthcare provider about any existing medical conditions, especially those related to skin infections or sensitivities. Following the prescribed dosage and application instructions is essential to prevent any adverse effects.
Do not use this drug if you have any allergies to Eucrisa or inactive ingredients. Hypersensitivity reactions may occur at the application site and can include redness, swelling, itching, hives, and trouble breathing.
Tell your doctor if you have any history of kidney problems because Eucrisa is mainly metabolized by the kidneys.
Common adverse reactions to this drug may include:
Eucrisa [package insert]. New York, NY: Pfizer; March 2020.